This publication evaluates the real-world use of non-invasive tests (LIVERFASt, FIB-4, and VCTE) in monitoring MASH patients undergoing resmetirom therapy. While FIB-4 and liver enzymes showed minimal change, LIVERFASt detected early improvements in steatosis over 6 months. The findings suggest LIVERFASt offers added sensitivity in tracking treatment response in non-cirrhotic MASH patients.